Takeda Pharmaceutical Company Limited American Depositary Shares (each

TAK Real Time Price USD
N/A
N/A
N/A
...
...
Overview
Financials
Forecast
Insiders
Institutions
Government
Ownership
News

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of TAK by members of U.S. Congress

Politician Type Traded
Virginia Foxx House / R Sale $15,001 - $50,000 Aug 29, 2023
Daniel S. Goldman House / D Sale $15,001 - $50,000 Jul 10, 2023
Virginia Foxx House / R Purchase $1,001 - $15,000 Feb 16, 2023
Virginia Foxx House / R Purchase $1,001 - $15,000 Nov 01, 2022
Greg Gianforte House / R Sale $1,001 - $15,000 Sep 11, 2019
Nicholas V. Taylor House / R Sale $15,001 - $50,000 Mar 25, 2019
Greg Gianforte House / R Purchase $15,001 - $50,000 Dec 21, 2018
TAK Stock Insider Trading Activity Follow @QuiverQuant for major insider updates
Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
TAK Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
TAK Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in TAK holdings by institutional investors

Insider Trading

Quarterly net insider trading by TAK's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions
  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $1,370,000 Oct 20, 2025 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Defense
  • $1,570,000 Aug 26, 2025 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Defense
  • $490,000 Apr 22, 2025 Issue: Budget/Appropriations Taxation/Internal Revenue Code Trade (domestic/foreign) Defense Medicare/Medicaid Health Issues
  • $390,000 Apr 18, 2025 Issue: Budget/Appropriations Medicare/Medicaid Health Issues Taxation/Internal Revenue Code Trade (domestic/foreign) Defense
  • $970,000 Oct 18, 2024 Issue: Budget/Appropriations Defense Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
  • $1,050,000 Jul 22, 2024 Issue: Defense Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
  • $460,000 Apr 22, 2024 Issue: Defense Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
  • $510,000 Jan 19, 2024 Issue: Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
  • $1,380,000 Oct 20, 2023 Issue: Budget/Appropriations Trade (domestic/foreign) Taxation/Internal Revenue Code Health Issues Medicare/Medicaid
Corporate Lobbying

TAK Estimated quarterly lobbying spending

Revenue Breakdown

TAK Revenue by Segment or Geography

By Segment
By Geography
TAK Income Statement
TAK Balance Sheet
TAK Cash Flow
U.S. Patents

New TAK patent grants

  • Patent Title: Display screen with a transitional graphical user interface Nov. 11, 2025
  • Patent Title: Display screen or portion thereof with graphical user interface Oct. 14, 2025
  • Patent Title: Display screen with a graphical user interface Oct. 14, 2025
  • Patent Title: Display screen or portion thereof with a graphical user interface Aug. 05, 2025
  • Patent Title: Display screen or portion thereof with graphical user interface Jul. 15, 2025
  • Patent Title: Medicament access device Jun. 10, 2025
  • Patent Title: Particle prevention adapter May. 06, 2025
  • Patent Title: Infusion pump cassette Oct. 29, 2024
  • Patent Title: Infusion pump Aug. 13, 2024
  • Patent Title: Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase May. 14, 2024
  • Patent Title: Infusion pump Apr. 16, 2024
  • Patent Title: Infusion pump Apr. 16, 2024
  • Patent Title: Display screen of a mobile phone with graphical user interface Mar. 19, 2024
  • Patent Title: Display screen with a transitional graphical user interface Jan. 23, 2024
  • Patent Title: Carrying case Oct. 31, 2023
  • Patent Title: Medicament access device Oct. 24, 2023
  • Patent Title: Nitrogen-containing heterocyclic compound and use of same Oct. 10, 2023
  • Patent Title: Particle prevention adapter Sep. 26, 2023
  • Patent Title: Fluid delivery device Jun. 13, 2023
  • Patent Title: Pusher foot for a fluid delivery device Jun. 28, 2022
  • Patent Title: Display screen with a transitional graphical user interface May. 31, 2022
  • Patent Title: Container unit Nov. 09, 2021
  • Patent Title: Nitrogen-containing heterocyclic compound and use of same Dec. 01, 2020
  • Patent Title: Heteroarylamide inhibitors of tbk1 Jun. 12, 2018
  • Patent Title: Condensed heterocyclic compound May. 22, 2018
  • Patent Title: Guanidinobenzoic acid ester compound May. 15, 2018
  • Patent Title: Fused heterocyclic compound May. 15, 2018
  • Patent Title: Radiolabeled compounds May. 08, 2018
  • Patent Title: Heterocyclic compound May. 01, 2018
  • Patent Title: 6-(5-hydroxy-1h-pyrazol-1-yl)nicotinamide inhibitors of phd Apr. 17, 2018
  • Patent Title: Heterocyclic compound Apr. 17, 2018
  • Patent Title: Method for producing sulfonyl chloride compound Apr. 03, 2018
  • Patent Title: Pyridazinone compounds and their use as daao inhibitors Apr. 03, 2018
  • Patent Title: Cyclopropanamine compound and use thereof Mar. 20, 2018
  • Patent Title: Sustained-release preparation Mar. 06, 2018
  • Patent Title: Orally disintegrable tablets Feb. 27, 2018
  • Patent Title: Heterocyclic compound Feb. 13, 2018
  • Patent Title: Heterocyclic compound and use thereof Feb. 06, 2018
  • Patent Title: Heterocyclic compound Jan. 30, 2018
  • Patent Title: Method for producing heterocyclic compound Jan. 30, 2018
  • Patent Title: Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimer's disease Jan. 16, 2018
  • Patent Title: Uti fusion proteins Jan. 02, 2018
  • Patent Title: Heterocyclic compound Dec. 05, 2017
  • Patent Title: Cyclic compounds Nov. 28, 2017
  • Patent Title: Fumagillol derivatives Nov. 28, 2017
  • Patent Title: Production method for poly(amino acid) Nov. 14, 2017
  • Patent Title: Process for producing heterocyclic compound Nov. 07, 2017
  • Patent Title: Pyridinyl and fused pyridinyl triazolone derivatives Oct. 31, 2017
  • Patent Title: Anti-cd38 antibodies Oct. 17, 2017
  • Patent Title: Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists Oct. 17, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to TAK from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
TAK News

Recent insights relating to TAK

CNBC Recommendations

Recent picks made for TAK stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in TAK

TAK Analyst Ratings

TAK Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
TAK Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $TAK stock a Buy, Sell, or Hold?

  • What is the price target for $TAK stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

TAK Top Shareholders
Shareholder
Shares Held
TAK Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $TAK stock?

  • Who owns the most shares of $TAK stock?

  • What funds own $TAK stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

TAK Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view TAK Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About TAK

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Back To Top